IO Biotech IOBTQ

IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines using its proprietary T-win platform. The company specializes in creating vaccines designed to target and eliminate both tumor cells and immune-suppressive cells within the tumor microenvironment, thereby enhancing the body’s natural anti-tumor immune response. IO Biotech’s approach centers on addressing key immunosuppressive pathways, such as indoleamine 2,3-dioxygenase (IDO) and programmed death ligand 1 (PD-L1), which are commonly exploited by cancers to evade immune detection. The company’s lead candidate, Cylembio, is being evaluated in advanced clinical trials for melanoma and other solid tumors, positioning IO Biotech at the forefront of immuno-oncology innovation.

IO Biotech generates revenue through partnerships, collaborations, and potential future commercialization of its therapeutic cancer vaccines. Currently, the company is pre-revenue, as its product candidates remain in clinical development. Revenue streams are expected to materialize upon regulatory approval and commercialization of its lead candidate, Cylembio, and other pipeline assets. The company’s business model includes strategic collaborations with pharmaceutical partners, such as Merck, which supplies pembrolizumab (KEYTRUDA) for clinical trials under supply agreements. Additionally, IO Biotech may explore licensing agreements, milestone payments, and royalties from future commercial sales of its approved therapies. The primary customers for IO Biotech’s products will be healthcare providers, hospitals, and oncology clinics treating patients with advanced or metastatic cancers.

The company operates through the following segments:

• Therapeutic Cancer Vaccines: This segment focuses on the development of immune-modulatory, off-the-shelf cancer vaccines designed to target immunosuppressive mechanisms within the tumor microenvironment. The lead candidate, Cylembio, combines two vaccine components, IO102 and IO103, which target IDO and PD-L1, respectively. Cylembio is currently in Phase 3 clinical trials for advanced melanoma and Phase 2 trials for non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). The segment also includes earlier-stage candidates, such as IO112, which targets Arginase 1, and IO170, which targets transforming growth factor beta 1 (TGFβ1).

• T-win Platform: This segment encompasses the company’s proprietary technology platform, which enables the rapid identification and development of therapeutic cancer vaccines. The T-win platform is designed to activate pre-existing T cells to target immunosuppressive cells and pathways within the tumor microenvironment, creating a pro-inflammatory environment that enhances anti-tumor activity. The platform supports the discovery of multiple pipeline candidates and is protected by a robust intellectual property portfolio, including 17 patent families filed across major global markets.

IO Biotech operates in the highly competitive immuno-oncology industry, where it competes with established pharmaceutical and biotechnology companies, as well as academic institutions and smaller biotech firms. Key competitors in the advanced melanoma space include Bristol-Myers Squibb (nivolumab and nivolumab/ipilimumab combinations), Merck (pembrolizumab), and Iovance Biotherapeutics (lifileucel). In NSCLC and SCCHN, competitors include AstraZeneca, Roche, and Regeneron, among others. IO Biotech’s competitive advantage lies in its unique T-win platform, which enables the development of off-the-shelf vaccines targeting multiple immunosuppressive pathways simultaneously. Unlike traditional checkpoint inhibitors, which block singular pathways, IO Biotech’s vaccines are designed to modulate the tumor microenvironment, potentially offering deeper and more durable responses with a favorable tolerability profile. The company’s lead candidate, Cylembio, has received Breakthrough Therapy Designation from the FDA for advanced melanoma, underscoring its potential to address unmet medical needs in oncology.

IO Biotech’s customer base primarily consists of oncology patients with advanced or metastatic cancers, including melanoma, NSCLC, and SCCHN. The company’s therapies are designed for use in combination with existing anti-PD-1 therapies, such as pembrolizumab, which are administered by healthcare providers in hospitals, clinics, and specialized cancer treatment centers. While the filing does not disclose specific customer names, IO Biotech’s clinical trials involve collaborations with leading academic institutions and medical centers globally. Upon commercialization, the company’s products are expected to be prescribed by oncologists and administered to patients who are candidates for immune checkpoint inhibitor therapies, particularly those with high unmet medical needs in first-line treatment settings.